Miyashita S, Kuno T, Takagi H, et al. - Via performing a meta-analysis, researchers examined if and how the use of sodium glucose co-transporter-2 (SGLT2) inhibitors is associated the amputation risk. Searching multiple databases up to February 2020, they included randomized controlled trials (RCTs) reporting risk of amputation with SGLT2 inhibitors vs non-SGLT2 inhibitors or placebo. They identified 1,873 citations in their initial search and included a total of five RCTs in the meta-analysis. The five included studies involved a total of 39,067 patients with diabetes mellitus; of these 21,395 patients were on SGLT2 inhibitors. The SGLT2 inhibitor group had amputation incidence ranging from 0.36 to 3.18% vs 0% to 2.87% in the control group. The meta-analysis revealed no correlation of either canagliflozin or of other SGLT2 inhibitors with increase in the risk of amputation.